[HTML][HTML] Lopinavir/ritonavir for COVID-19: a living systematic review
Objective Provide a timely, rigorous, and continuously updated summary of the evidence on
the role of lopinavir/ritonavir in the treatment of patients with COVID-19. Methods We …
the role of lopinavir/ritonavir in the treatment of patients with COVID-19. Methods We …
[HTML][HTML] The future of Paxlovid for COVID-19
T Burki - The Lancet Respiratory Medicine, 2022 - thelancet.com
In comments to Bloomberg published on May 3, 2022, Pfizer chief executive officer Albert
Bourla suggested that patients who experience a relapse of symptoms after finishing a …
Bourla suggested that patients who experience a relapse of symptoms after finishing a …
Covid-19: What is the evidence for the antiviral Paxlovid?
A Extance - Bmj, 2022 - bmj.com
Covid-19: What is the evidence for the antiviral Paxlovid? | The BMJ Skip to main content
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …
Intended for healthcare professionals Access provided by Google Indexer Subscribe My …
[HTML][HTML] The global COVID-19 treatment divide
AD Usher - The Lancet, 2022 - thelancet.com
The brutal logic that has divided the world into vaccine haves and havenots is now being
repeated as gamechanging COVID-19 drugs like Pfizer's oral antiviral Paxlovid (nirmatrelvir …
repeated as gamechanging COVID-19 drugs like Pfizer's oral antiviral Paxlovid (nirmatrelvir …
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
The COVID-19 pandemic is one of the greatest threats to human health in the 21st century
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
with more than 257 million cases and over 5.17 million deaths reported worldwide (as of …
[HTML][HTML] Proxalutamide significantly accelerates viral clearance and reduces time to clinical remission in patients with mild to moderate COVID-19: results from a …
Background The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
into type II pneumocytes is dependent on a modification of viral spike proteins by …
into type II pneumocytes is dependent on a modification of viral spike proteins by …
[HTML][HTML] COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022
L Wang, NA Berger, PB Davis, DC Kaelber, ND Volkow… - MedRxiv, 2022 - ncbi.nlm.nih.gov
COVID-19 rebound after Paxlovid and Molnupiravir during January-June 2022 - PMC Back
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
to Top Skip to main content NIH NLM Logo Access keys NCBI Homepage MyNCBI …
Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports
E Mahase - 2021 - bmj.com
Pfizer's oral antiviral drug paxlovid significantly reduces hospital admissions and deaths
among people with covid-19 who are at high risk of severe illness, when compared with …
among people with covid-19 who are at high risk of severe illness, when compared with …
Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial
H Bian, ZH Zheng, D Wei, Z Zhang, WZ Kang, CQ Hao… - medrxiv, 2020 - medrxiv.org
Background SARS-CoV-2 is a novel human coronavirus, there is no specific antiviral drugs.
It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 …
It has been proved that host-cell-expressed CD147 could bind spike protein of SARS-CoV-2 …
[HTML][HTML] The emergence of powerful oral anti-COVID-19 drugs in the post-vaccine era
The quest for effective drugs to treat COVID-19 has been a priority since the outbreak of the
disease. The clinical application of remdesivir has been greatly restricted by the need for …
disease. The clinical application of remdesivir has been greatly restricted by the need for …